GREM1 是膀胱癌进展和预后的潜在生物标志物。

GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.

机构信息

Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, People's Republic of China.

出版信息

World J Surg Oncol. 2023 Aug 22;21(1):255. doi: 10.1186/s12957-023-03128-0.

BACKGROUND

Gremlin-1 (GREM1) is a protein closely related to tumor growth, although its function in bladder cancer (BCa) is currently unknown. Our first objective was to study the GREM1 treatment potential in BCa.

METHODS

BCa tissue samples were collected for the detection of GREM1 expression using Western blot analysis and Immunofluorescence staining. Association of GREM1 expression with clinicopathology and prognosis as detected by TCGA (The Cancer Genome Atlas) database. The functional investigation was tested by qRT-PCR, western blot analysis, CCK-8, cell apoptosis, wound healing, and transwell assays. The interaction between GREM1 and the downstream PI3K/AKT signaling pathway was assessed by Western blot analysis.

RESULTS

GREM1 exhibited high expression in BCa tissues and was linked to poor prognosis. Stable knockdown of GREM1 significantly inhibited BCa cell (T24 and 5637) proliferation, apoptosis, migratory, invasive, as well as epithelial-mesenchymal transition (EMT) abilities. GREM1 promotes the progression in BCa via PI3K/AKT signaling pathway.

CONCLUSION

Findings demonstrate that the progression-promoting effect of GREM1 in BCa, providing a novel biomarker for BCa-targeted therapy.

背景

Gremlin-1（GREM1）是一种与肿瘤生长密切相关的蛋白，尽管其在膀胱癌（BCa）中的功能目前尚不清楚。我们的首要目标是研究 GREM1 在 BCa 中的治疗潜力。

方法

使用 Western blot 分析和免疫荧光染色检测 BCa 组织样本中 GREM1 的表达。通过 TCGA（癌症基因组图谱）数据库检测 GREM1 表达与临床病理和预后的相关性。通过 qRT-PCR、Western blot 分析、CCK-8、细胞凋亡、伤口愈合和 Transwell 测定来测试功能研究。通过 Western blot 分析评估 GREM1 与下游 PI3K/AKT 信号通路之间的相互作用。